407 related articles for article (PubMed ID: 26903516)
21. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
22. The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.
Amos N; Sissons JG; Girard JF; Lachmann PJ; Peters DK
Clin Exp Immunol; 1976 Jun; 24(3):474-82. PubMed ID: 939051
[TBL] [Abstract][Full Text] [Related]
23. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
24. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.
Heurich M; Martínez-Barricarte R; Francis NJ; Roberts DL; Rodríguez de Córdoba S; Morgan BP; Harris CL
Proc Natl Acad Sci U S A; 2011 May; 108(21):8761-6. PubMed ID: 21555552
[TBL] [Abstract][Full Text] [Related]
25. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
26. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
Pryzdial EL; Isenman DE
J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
[TBL] [Abstract][Full Text] [Related]
27. The inhibitory effect of factor J on the alternative complement pathway.
González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
[TBL] [Abstract][Full Text] [Related]
28. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
29. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
Schreiber RD; Pangburn MK; Lesavre PH; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3948-52. PubMed ID: 279011
[TBL] [Abstract][Full Text] [Related]
30. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
31. Control of the amplification convertase of complement by the plasma protein beta1H.
Weiler JM; Daha MR; Austen KF; Fearon DT
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
[TBL] [Abstract][Full Text] [Related]
32. Autoantibodies against complement factor B in rheumatoid arthritis.
Matola AT; Fülöp A; Rojkovich B; Nagy G; Sármay G; Józsi M; Uzonyi B
Front Immunol; 2023; 14():1113015. PubMed ID: 36891314
[TBL] [Abstract][Full Text] [Related]
33. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes.
Mold C; Medof ME
Mol Immunol; 1985 May; 22(5):507-12. PubMed ID: 3848661
[TBL] [Abstract][Full Text] [Related]
34. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.
Tanuma Y; Ohi H; Hatano M
Immunology; 1989 Dec; 68(4):445-8. PubMed ID: 2532618
[TBL] [Abstract][Full Text] [Related]
36. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
37. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
38. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
[TBL] [Abstract][Full Text] [Related]
39. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
40. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
